Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06041789 · ClinicalTrials.gov registry record · Phase 2
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
A Phase 2 study of Osteoporosis, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06041789: Recruiting Phase 2 study of Osteoporosis, sponsored by Duke University.
NCT06041789 is a Phase 2 study of Osteoporosis that is actively recruiting participants, run by Duke University. The registered enrollment target is 45 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06041789, a Phase 2 study of Osteoporosis, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have shown that those taking donepezil have a lower rate of bone fractures, but the reasons for this are unknown. The purpose of this study is to measure the effect of donepezil treatment on bone metabolism factors including bone mineral density, bone turnover markers, and bone quality. Participants in this study will have a bone density test and have blood samples collected at the baseline study visit. Participants will then be randomly assigned to donepezil or matching memantine to be taken daily by mouth for 12 months. Blood samples will be collected at 6 and 12 months. A repeat bone density test will be performed at 12 months. Participants will also complete questionnaires at each study visit.
Conditions Studied
Interventions
- DRUG Memantine
- DRUG Donepezil
Study Locations (1)
North Carolina
- Duke Memory Disorders Clinic - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT06041789 shows while recruiting
NCT06041789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Memantine is the first listed.
NCT06041789 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06041789 about?
NCT06041789 is a clinical study titled "Effect of Acetylcholinesterase Inhibitors on Bone Metabolism". People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have shown that those taking donepezil have a lower rate of bone fractures, but the reasons for this are unknown. The purpose of this study is to measure the effect of donepezil treatment on bone metabolism facto...
What is the current status of trial NCT06041789?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-02-03. Estimated completion is 2026-11.
What conditions does trial NCT06041789 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT06041789?
The interventions under investigation include: Memantine (DRUG), Donepezil (DRUG).
Who is sponsoring clinical trial NCT06041789?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06041789 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06041789's enrollment target sits among peer trials
45 59th of 84 higher than 24 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Calcium and Bone Mass in Young Females
COMPLETED · Phase 2
-
Comparison Study of PTHrP and PTH to Treat Osteoporosis
COMPLETED · Phase 2
-
Hormone Replacement Therapy to Treat Turner Syndrome
COMPLETED · Phase 2
-
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
COMPLETED · Phase 2
-
12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 2
-
Adding Phosphorus to Osteoporosis Drug Treatment
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI